Last update 16 Nov 2024

Birch pollen allergy immunotherapy(LETI Pharma GmbH)

Overview

Basic Info

Drug Type
Allergen extract
Synonyms
Birch pollen allergy immunotherapy, Depigoid Birch, Depigoid Birch 5000
Target-
Mechanism
Immunomodulators
Therapeutic Areas
Immune System DiseasesInfectious DiseasesCongenital Disorders+ [4]
Active Indication
RhinoconjunctivitisConjunctivitis, AllergicDermatitis, Atopic
Inactive Indication
Rhinitis, Allergic, Seasonal
Originator Organization
LETI Pharma GmbH
Active Organization
LETI Pharma GmbH
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with Birch pollen allergy immunotherapy(LETI Pharma GmbH)
EUCTR2012-000414-11-FI / Not yet recruitingPhase 3
Multicenter, placebo-controlled, long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma - Depigoid Birch
NCT01694836 / CompletedPhase 3
Multicenter, Placebo-controlled, Long-term Study of Depigoid Birch 5000 in Adults and Adolescents With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma
EUCTR2012-000414-11-LT / Not yet recruitingPhase 3
Multicenter, placebo-controlled, long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma - Depigoid Birch
100 Clinical Results associated with Birch pollen allergy immunotherapy(LETI Pharma GmbH)
Login to view more data
100 Translational Medicine associated with Birch pollen allergy immunotherapy(LETI Pharma GmbH)
Login to view more data
100 Patents (Medical) associated with Birch pollen allergy immunotherapy(LETI Pharma GmbH)
Login to view more data
100 Deals associated with Birch pollen allergy immunotherapy(LETI Pharma GmbH)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RhinoconjunctivitisPhase 3
DE
LETI Pharma GmbH
30 Sep 2012
Rhinitis, Allergic, SeasonalPhase 3
CZ
LETI Pharma GmbH
14 Jul 2012
Conjunctivitis, AllergicPhase 3-
LETI Pharma GmbH
-
Dermatitis, AtopicPhase 3-
LETI Pharma GmbH
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free